Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 9/20 | 0.66 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.66 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.66 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.61 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.58 |
| ▸ | NAMPT | P43490 | 1/20 | 0.57 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21845748 | 0.91 | JAK2 (0.59) | DRD4SLC6A12SLC6A13MCHR1ACKR3 | |
| SCHEMBL25875888 | 0.84 | MAOA (0.53) | ACKR3SIGMAR1CYP1A2MAPK1 | |
| SCHEMBL25875908 | 0.82 | NPC1 (0.69) | MAPK1 | |
| SCHEMBL25478350 | 0.76 | DEGS1 (0.68) | NAMPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL25875892 | 0.76 | CYP1A2 (0.64) | CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL61848 | 0.75 | TMEM97 (0.83) | DRD4SLC6A12SLC6A13MCHR1TMEM97 | |
| SCHEMBL694949 | 0.75 | SIGMAR1 (0.82) | DRD4SLC6A12SLC6A13MCHR1TMEM97 | |
| SCHEMBL22752022 | 0.75 | JAK2 (0.69) | — | |
| SCHEMBL22857550 | 0.75 | JAK2 (0.69) | — | |
| SCHEMBL25875911 | 0.75 | CYP1A2 (0.56) | NAMPTCYP1A2CYP2D6TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227430-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | ALCON INC. (CH) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227430-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | UACA, CHUK, MAP3K2 | DRD4 4821/4885SLC6A12 4850/4885SLC6A13 4774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.